Chemomab Therapeutics
CMMB
16 hedge funds and large institutions have $15.9M invested in Chemomab Therapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
14% more funds holding
Funds holding: 14 → 16 (+2)
0% more ownership
Funds ownership: 0.36% → 0.36% (+0%)
30% less capital invested
Capital invested by funds: $22.7M → $15.9M (-$6.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$1.42M |
| 2 |
Renaissance Technologies
New York
|
+$138K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$62.3K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$53.3K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$1.31M |
| 2 |
VF
Virtu Financial
New York
|
-$155K |
| 3 |
AWM
Apollon Wealth Management
Mount Pleasant,
South Carolina
|
-$83K |
| 4 |
Morgan Stanley
New York
|
-$80K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$78K |
CMMB Hedge Fund Activity: Q1 2022 in Review
16 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q1 2022, worth a combined $15.9M — down 30% from $22.7M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CMMB positions and 5 closed out — a net gain of 2 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $1.42M. The largest seller was ARK Investment Management, cutting an estimated $1.31M.
- 16 institutional investors held Chemomab Therapeutics (CMMB) as of Q1 2022, up from 14 in Q4 2021.
- Funds reported $15.9M of Chemomab Therapeutics stock for Q1 2022, down 30% quarter-over-quarter.
- 7 funds opened new Chemomab Therapeutics positions in Q1 2022 and 5 closed out, a net change of +2 holders.
- The largest Chemomab Therapeutics buyer in Q1 2022 was Cormorant Asset Management, an estimated $1.42M added.
- The largest Chemomab Therapeutics seller in Q1 2022 was ARK Investment Management, an estimated $1.31M sold.
Based on aggregated 13F filings for Q1 2022.